- Home
- INKT vs CVKD Comparison
INKT vs CVKD Comparison
Compare INKT & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- CVKD
- Stock Information
- Founded
- INKT 2017
- CVKD 2022
- Country
- INKT United States
- CVKD United States
- Employees
- INKT N/A
- CVKD N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- INKT Health Care
- CVKD Health Care
- Exchange
- INKT Nasdaq
- CVKD Nasdaq
- Market Cap
- INKT 28.8M
- CVKD 29.5M
- IPO Year
- INKT 2021
- CVKD 2023
- Fundamental
- Price
- INKT $62.86
- CVKD $12.71
- Analyst Decision
- INKT Strong Buy
- CVKD Strong Buy
- Analyst Count
- INKT 2
- CVKD 1
- Target Price
- INKT $37.50
- CVKD $32.00
- AVG Volume (30 Days)
- INKT 2.4M
- CVKD 36.2K
- Earning Date
- INKT 08-12-2025
- CVKD 08-06-2025
- Dividend Yield
- INKT N/A
- CVKD N/A
- EPS Growth
- INKT N/A
- CVKD N/A
- EPS
- INKT N/A
- CVKD N/A
- Revenue
- INKT N/A
- CVKD N/A
- Revenue This Year
- INKT N/A
- CVKD N/A
- Revenue Next Year
- INKT N/A
- CVKD N/A
- P/E Ratio
- INKT N/A
- CVKD N/A
- Revenue Growth
- INKT N/A
- CVKD N/A
- 52 Week Low
- INKT $4.56
- CVKD $5.70
- 52 Week High
- INKT $76.00
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- INKT 57.39
- CVKD 49.98
- Support Level
- INKT $6.80
- CVKD $11.00
- Resistance Level
- INKT $7.88
- CVKD $13.56
- Average True Range (ATR)
- INKT 0.40
- CVKD 1.15
- MACD
- INKT 0.02
- CVKD 0.25
- Stochastic Oscillator
- INKT 58.86
- CVKD 80.97
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.